Breaking new ground: bringing an iPS cell therapy to the clinicPublished: October 29, 2019
Clinical Trial Designs For Advanced Therapies
Kapil Bharti holds a bachelor’s degree in biophysics from the Panjab University in Chandigarh, India, where he graduated with highest honors. This was followed by a Masters degree in biotechnology at the Maharaja Sayaji Rao University in Baroda, India and a diploma in molecular cell biology at the Johann Wolfgang Goethe University at Frankfurt in Germany. Supported by an international PhD student fellowship, he obtained his PhD from the same institution, graduating summa cum laude. His PhD work involved basic biology in the areas of heat stress, cellular chaperones, and epigenetics. From Germany, Dr Bharti came to the National Institute of Neurological Disorders and Stroke to work with Dr Heinz Arnheiter as a postdoctoral fellow. While there, he published numerous papers in the areas of transcription factor regulation, pigment cell biology, and the developmental biology of the eye. It is perhaps this combination of diverse backgrounds that led him to develop an interest in the emerging field of stem cell biology, particularly of the retinal pigment epithelium, as he moved into the role of staff scientist. Dr Bharti has authored numerous publications and has won several awards, including, most recently, being a finalist in the prestigious trans-NIH Earl Stadtman Symposium.DOI: 10.18609/cgti.2019.142
Citation: Cell & Gene Therapy Insights 2019; 5(11), 1369-1375.